GTI 2040
Product Specifications
UNSPSC Description
GTI-2040, a 20-mer phosphorothioate oligonucleotide, was designed to hybridize to the mRNA sequence of human ribonucleotide reductase R2. GTI-2040 has been shown to inhibit human cancer cell proliferation by downregulation of R2 expression in vitro and to significantly inhibit tumor growth in xenograft models of human cancer in mice.
Target Antigen
Others
Type
Oligonucleotides
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/gti-2040.html
Solubility
10 mM in H2O
Smiles
[GTI 2040]
References & Citations
[1]Vassilakos A, Lee Y, Viau S, et al. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts. Int J Oncol. 2009;34(1):33-42.|[2]Ferdinandi ES, Vassilakos A, Lee Y, et al. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother Pharmacol. 2011;68(1):193-205. doi:10.1007/s00280-010-1473-z
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153834/GTI-2040-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153834/
Clinical Information
No Development Reported
CAS Number
236391-66-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
AVARP01005_P050-FITC 100 µL
BCL2 Antibody - N-terminal region: FITC (AVARP01005_P050-FITC)
Ask
View Details 